DK2806889T3 - Polynukleotider til behandling af onkogene virale polypeptidpositive tumorer - Google Patents
Polynukleotider til behandling af onkogene virale polypeptidpositive tumorerInfo
- Publication number
- DK2806889T3 DK2806889T3 DK13740950.4T DK13740950T DK2806889T3 DK 2806889 T3 DK2806889 T3 DK 2806889T3 DK 13740950 T DK13740950 T DK 13740950T DK 2806889 T3 DK2806889 T3 DK 2806889T3
- Authority
- DK
- Denmark
- Prior art keywords
- polynucleotides
- treatment
- positive tumors
- viral polypeptide
- oncogenic viral
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 231100000590 oncogenic Toxicity 0.000 title 1
- 230000002246 oncogenic effect Effects 0.000 title 1
- 102000040430 polynucleotide Human genes 0.000 title 1
- 108091033319 polynucleotide Proteins 0.000 title 1
- 239000002157 polynucleotide Substances 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 230000003612 virological effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20071—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261590089P | 2012-01-24 | 2012-01-24 | |
| PCT/US2013/022696 WO2013112549A1 (en) | 2012-01-24 | 2013-01-23 | Polynucleotides for treating oncogenic viral polypeptide positive tumors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2806889T3 true DK2806889T3 (da) | 2017-11-20 |
Family
ID=48873849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13740950.4T DK2806889T3 (da) | 2012-01-24 | 2013-01-23 | Polynukleotider til behandling af onkogene virale polypeptidpositive tumorer |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US9492526B2 (enExample) |
| EP (2) | EP2806889B1 (enExample) |
| JP (2) | JP6219849B2 (enExample) |
| KR (1) | KR102195196B1 (enExample) |
| CN (2) | CN104159607A (enExample) |
| DK (1) | DK2806889T3 (enExample) |
| ES (1) | ES2646590T3 (enExample) |
| HK (1) | HK1203833A1 (enExample) |
| IN (1) | IN2014DN06118A (enExample) |
| WO (1) | WO2013112549A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2811093T3 (es) | 2014-11-13 | 2021-03-10 | Univ Geneve | Arenavirus trisegmentados como vectores de vacunas |
| HK1246183A1 (zh) | 2015-06-10 | 2018-09-07 | Hookipa Biotech Gmbh | Hpv疫苗 |
| WO2017076988A1 (en) | 2015-11-04 | 2017-05-11 | Hookipa Biotech Ag | Vaccines against hepatitis b virus |
| EP3373959B1 (en) | 2015-11-12 | 2022-06-29 | Hookipa Biotech GmbH | Arenavirus particles as cancer vaccines |
| JP2019505512A (ja) | 2016-01-08 | 2019-02-28 | バッシボディ アクスイェ セルスカプ | 治療用抗癌ネオエピトープワクチン |
| GB201605210D0 (en) | 2016-03-29 | 2016-05-11 | Oxford Immunotec Ltd | Assay |
| JP2019517522A (ja) * | 2016-06-03 | 2019-06-24 | エトゥビクス コーポレーション | ヒトパピローマウイルス（ｈｐｖ）関連疾患の処置のための組成物及び方法 |
| CN106655327A (zh) * | 2016-10-18 | 2017-05-10 | 云南中烟工业有限责任公司 | 一种压缩式充电装置 |
| CN109891405B (zh) * | 2016-11-11 | 2023-09-26 | 谷歌有限责任公司 | 基于用户装置的消费模式来修改视频内容在用户装置上的呈现的方法、系统和介质 |
| SG11202008539YA (en) | 2018-03-06 | 2020-10-29 | Precigen Inc | Human papillomavirus vaccines and uses of the same |
| IL296509A (en) | 2020-03-16 | 2022-11-01 | Univ North Carolina Chapel Hill | Preparations and methods for selective detection of tumor-derived viral DNA |
| WO2021205027A1 (en) | 2020-04-09 | 2021-10-14 | Vaccibody As | Individualized therapeutic anticancer vaccine |
| AU2021281910C1 (en) * | 2020-05-25 | 2024-09-19 | Genematrix Inc. | Structurally modified chimeric polypeptide of human papillomavirus, recombinant protein comprising same polypeptide, and use of same protein |
| KR102712588B1 (ko) * | 2020-05-25 | 2024-10-02 | (주)진매트릭스 | 사람 파필로마바이러스의 구조적으로 변형된 키메라 폴리펩타이드 및 그 폴리펩타이드를 포함하는 재조합 단백질 및 그 단백질의 용도 |
| CN116425839A (zh) * | 2023-04-03 | 2023-07-14 | 深圳锦时生物科技有限公司 | 人乳头瘤病毒多肽及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9717953D0 (en) * | 1997-08-22 | 1997-10-29 | Smithkline Beecham Biolog | Vaccine |
| WO1999061608A2 (en) * | 1998-05-26 | 1999-12-02 | Institute Of Molecular And Cell Biology | Polypeptides from creb binding protein and related protein p300 for use in transcriptional regulation |
| CA2499837C (en) * | 2002-10-03 | 2013-12-03 | Wyeth Holdings Corporation | Human papillomavirus polypeptides and immunogenic compositions |
| KR101514473B1 (ko) * | 2007-05-15 | 2015-04-22 | 트랜스진 에스.에이. | 다중 유전자 발현용 벡터 |
| WO2010129339A2 (en) * | 2009-04-28 | 2010-11-11 | The Johns Hopkins University | Compositions and methods for enhancing antigen-specific immune responses |
| CN102002105B (zh) * | 2009-09-03 | 2013-01-23 | 中国疾病预防控制中心病毒病预防控制所 | Hpv 16型e7e6融合蛋白基因、表达载体、方法、细胞和用途 |
-
2013
- 2013-01-23 CN CN201380012419.2A patent/CN104159607A/zh active Pending
- 2013-01-23 WO PCT/US2013/022696 patent/WO2013112549A1/en not_active Ceased
- 2013-01-23 EP EP13740950.4A patent/EP2806889B1/en active Active
- 2013-01-23 KR KR1020147023589A patent/KR102195196B1/ko active Active
- 2013-01-23 US US14/373,844 patent/US9492526B2/en active Active
- 2013-01-23 HK HK15104469.7A patent/HK1203833A1/xx unknown
- 2013-01-23 IN IN6118DEN2014 patent/IN2014DN06118A/en unknown
- 2013-01-23 JP JP2014554791A patent/JP6219849B2/ja active Active
- 2013-01-23 CN CN201910216555.2A patent/CN110042110A/zh active Pending
- 2013-01-23 ES ES13740950.4T patent/ES2646590T3/es active Active
- 2013-01-23 EP EP17185609.9A patent/EP3269387B1/en active Active
- 2013-01-23 DK DK13740950.4T patent/DK2806889T3/da active
-
2016
- 2016-09-06 US US15/257,198 patent/US9969779B2/en active Active
-
2017
- 2017-09-28 JP JP2017188121A patent/JP6655051B2/ja active Active
-
2018
- 2018-04-11 US US15/950,819 patent/US20180237477A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2806889A1 (en) | 2014-12-03 |
| EP2806889B1 (en) | 2017-08-16 |
| CN104159607A (zh) | 2014-11-19 |
| IN2014DN06118A (enExample) | 2015-08-14 |
| JP2015506179A (ja) | 2015-03-02 |
| CN110042110A (zh) | 2019-07-23 |
| EP2806889A4 (en) | 2016-04-20 |
| US9969779B2 (en) | 2018-05-15 |
| US9492526B2 (en) | 2016-11-15 |
| JP2018038405A (ja) | 2018-03-15 |
| KR102195196B1 (ko) | 2020-12-28 |
| US20180237477A1 (en) | 2018-08-23 |
| EP3269387B1 (en) | 2019-07-17 |
| KR20140131929A (ko) | 2014-11-14 |
| HK1203833A1 (en) | 2015-11-06 |
| US20150023996A1 (en) | 2015-01-22 |
| JP6219849B2 (ja) | 2017-10-25 |
| ES2646590T3 (es) | 2017-12-14 |
| WO2013112549A1 (en) | 2013-08-01 |
| JP6655051B2 (ja) | 2020-02-26 |
| US20160376324A1 (en) | 2016-12-29 |
| EP3269387A1 (en) | 2018-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL289300A (en) | Combination therapy for treating cancer | |
| DK2897620T3 (da) | Fremgangsmåde til behandling af cancer | |
| DK3033086T3 (da) | Kombinationsterapi til behandling af cancer | |
| DK3043816T3 (da) | Anti-b7-h1-antistoffer til behandling af tumorer | |
| LT3456831T (lt) | Tikslinis žiurkės genomo modifikavimas | |
| DK2818482T3 (da) | Farmaceutisk sammensætning til behandling af cancer | |
| IL237275A0 (en) | Compounds for the treatment of paramoxovirus viral infections | |
| DK2824114T3 (da) | Farmaceutisk sammensætning til behandling af cancer | |
| DK3006568T3 (da) | Fremgangsmåde til fremstilling af tagatose | |
| DK2900061T3 (da) | Fremgangsmåde til forstærkning af specifikke immunterapier ved cancerbehandling | |
| DK2840065T3 (da) | Fremgangsmåde til fremstilling af præcipiteret calciumcarbonat | |
| DK2908904T3 (da) | System til styring af vævs elektriske tilstand | |
| DK3329884T3 (da) | Implanterbar indretning til behandling af glaukom | |
| DK3046583T3 (da) | Viruslignende partikelkonjugater til behandling af tumorer | |
| DK3076976T3 (da) | Fremgangsmåder til behandling af cancer | |
| DK3076967T3 (da) | Fremgangsmåder til behandling af residuelle symptomer på skizofreni | |
| EP2806889A4 (en) | POLYNUCLEOTIDES FOR THE TREATMENT OF VIRAL ONKOGENIC POLYPEPTIDE POSITIVE TUMORS | |
| DK3054976T3 (da) | Anvendelse af semaphorin-4d-bindende molekyler til behandling af aterosklerose | |
| DK2901341T3 (da) | Identifikation af tumorbeskyttelsesepitoper til behandling af cancere | |
| DK2882444T3 (da) | Mikroporøs zirconiumsilikat til behandling af hyperkaliæmi | |
| DK2861240T3 (da) | Nukleinsyrer til behandling af allergier | |
| DK2976359T4 (da) | Fremgangsmåder til behandling af osteogenesis imperfecta | |
| EP2922564A4 (en) | ONCOLYTIC POLIOVIRUS FOR HUMAN TUMORS | |
| DK3456330T3 (da) | Cortexolon-17alpha-valerat til anvendelse ved behandling af tumorer | |
| DK3010895T3 (da) | Fremgangsmåde til fremstilling af 4-propargyleret aminobenzoxazinoner |